Qyuns Therapeutics Co., Ltd. disclosed that on 28 May 2026 it bought back 70,000 H-shares on the Hong Kong Stock Exchange at prices ranging from HKD 16.21 to HKD 16.60 per share, for a total consideration of HKD 1.16 million. The volume-weighted average cost was HKD 16.52 per share.

Following the transaction, outstanding shares (excluding treasury stock) fell to 224.36 million, while treasury shares increased to 2.71 million. The company’s total issued share capital remains unchanged at 227.07 million shares, with the latest repurchase representing 0.03 % of the issued shares outstanding prior to the buyback.

The purchases were made under the general mandate approved on 20 June 2025, which authorises the company to repurchase up to 22.21 million shares. Including the latest operation, Qyuns Therapeutics has repurchased 2.71 million shares to date, equivalent to 1.22 % of the issued share count on the mandate’s approval date.

In accordance with Hong Kong Listing Rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 27 June 2026. The repurchased shares will be held as treasury stock; none have been cancelled as of the disclosure date.